IL18 and hemophilia: These results align with findings by Wehmeier et al. [16], who reported elevated IL-18 in hemophilia and emphasized its role in neuroinflammation and disease progression; experimental IL-18 blockade reduced neuropathic pain and increased opioid efficacy.